Medicine@Yale U

Total Page:16

File Type:pdf, Size:1020Kb

Medicine@Yale U Medicine@Ya le Advancing Biomedical Science, Education and Health Care Volume 1, Issue 2 August/September 2005 New look at how resistant bugs dodge drugs Yale biologists have opened a new Many widely used antibiotics mined the atomic-level structure of front in the war on antibiotic- work by latching onto and inhibiting five common antibiotics when the resistant bacteria by creating the first ribosomes, the protein factories drugs were bound to the ribosomes high-resolution pictures that show present in all cells. Using X-ray crys- of sensitive or resistant bacteria. how some resistant bacterial strains, tallography, Thomas A. Steitz, .., Although the antibiotics used in which threaten to undo years of Sterling Professor of Molecular the study have quite different chemi- progress against infectious disease, Biophysics and Biochemistry and a cal structures, Steitz and Moore thwart commonly used antibiotics. Howard Hughes Medical Institute found that they all bind to the same The new research, published in investigator, and Peter B. Moore, site on the ribosome’s large subunit In the ribosome of a resistant bacterium the April issue of Cell, provides .., Sterling Professor of and that resistance to all of them is (lower left), a “bulge” (red area at center) scientists with a fresh battle plan for Chemistry and professor of molecular generated by the same change in just keeps the antibiotic erythromycin (upper right) from binding tightly. creating new antimicrobial drugs. biophysics and biochemistry, deter- Ribosome, page 8 YALE PROJECTS FOR GLOBAL HEALTH RECEIVE MAJOR FUNDING Using laser light, team guides flies by remote control Researchers at the School of Medicine Richard Flavell will have created a high-tech puppet show, spearhead a new only their marionettes are alive and approach to vaccine development with a have no strings attached. With the $17 million grant from help of some genetic tweaking, the the Grand Challenges in team got fruit flies to walk, jump and Global Health initiative, fly on command—simply by flashing which is supported by a light at them. the Bill and Melinda Gates Foundation, the Over centuries, to better under- Wellcome Trust and the stand the brain’s normal functions Canadian Institutes of and the roots of disease, scientists Health Research and have devised many methods of managed by the manipulating animal behavior, but Foundation of the National Institutes they have had to rely on invasive tech- of Health. Flies, page 7 Mouse breakthrough will speed vaccines Fund will honor mentor, aid students All progress in biomedicine is made been subjected to over evolutionary on the horns of a dilemma. The Foiling malaria mosquitoes, p. 6 time, not the same set of pathogens This spring, when Applera Corp. of testing of drugs or other therapies that infect humans. And, as its Foster City, Calif., asked members of in humans before they are shown gap in knowledge, and only a small name implies, the immune system its board of directors to suggest likely to be safe and therapeutically fraction of the drugs that enter isn’t a unitary organ like the liver, worthy recipients for gifts from the promising in preclinical studies is clinical testing are eventually but a multifaceted mechanism dis- corporation, Carolyn W. Slayman, prohibited by ethical considera- approved for use in medicine. tributed throughout the body, .., the medical school’s deputy tions. But the tools available for This state of affairs has pre- which is difficult to emulate faith- dean for academic and scientific preclinical work—laboratory sented particular challenges in fully in a petri dish. affairs, suggested a grant that would animals or isolated cells in a dish— immunology research, says Richard “You don’t really want to be do double duty to promote her ideals are no substitute for testing in the A. Flavell, .., chair and Sterling studying mouse cells; you want to in biomedical education. living human body. Professor of Immunobiology. Mice, study human cells, and ultimately Slayman, a director of Applera— Bringing a potential cure from the most commonly used research you study humans, in clinical the parent company of Applied laboratory science to human clini- animal, have immune systems that trials,” says Flavell, who is also a Biosystems, a manufacturer of scien- cal trials often requires an unset- are tailored to deal with the bacte- Howard Hughes Medical Institute tific equipment, and Celera, which tling leap across an unavoidable ria and viruses that the species has Flavell, page 6 played a major role in sequencing the Fund, page 6 Non-Profit Org. Inside this issue Medicine@Yale U. S. Postage Lifelines Strength in numbers P.O.Box PAID Arthur Horwich, seeking what’s Adding up proteins brings power New Haven, CT New Haven, CT never been seen, p. 2 to ovarian cancer test, p. 5 www.medicineatyale.org Permit No. In praise of talented teachers A demand for supplies Faculty are feted at Medical equipment reaches Commencement, p. 2 the needy,p.5 Tracking down autism Also A hunt for childhood disorder’s Advances, pp. 3, 5; Out & About,p.4; first traces, p. 3 Grants, p. 7; Awards, p. 8 Want to find out more about medicine at Yale? E-mail us at [email protected] or phone (203) 785-5824. Notable teachers Form leads receive high honors to function at Commencement At the medical school’s Commence- Solving the puzzles of ment ceremony on Harkness Lawn in protein folding may shed May, the Class of enjoyed their new light on Alzheimer’s day in the sun, basking in the admira- tion of family and It’s true that biologist Arthur L. friends. But faculty, Horwich, m.d., received last year’s too, were honored for Gairdner International Award for their many contribu- having “revolutionized our under- tions to education. standing about basic cellular func- For the first time, tions,” but to hear him talk, he’s not the Bohmfalk Prize Peter Aronson much different for teaching basic sci- from the twenty- Lifelines ences was awarded to something post- a husband-and- doctoral re- Arthur L. wife team, Marie- searchers who Horwich Arthur Horwich (third from right) in his element—amongst the graduate students, postdoc- Louise Landry, .., staff his lab. toral fellows and research scientists with whom he shares the lab bench. “I just have never matured beyond professor of labora- postdoc,” says Horwich, the Eugene Christian B. Anfinsen, ph.d., who P. Lifton, m.d., ph.d., an hhmi tory medicine, and Higgins Professor of Genetics, profes- showed in the early 1960s that the investigator who is chair and Peter S. Aronson, Marie-Louise Landry sor of pediatrics and a Howard Hughes sequence of amino acids in a nascent Sterling Professor of Genetics at .., the ...Long Medical Institute (hhmi) investigator. protein contains all the information it the medical school. Professor of Medicine and professor “I still work at the bench every day. I needs to fold from a chain into the Colleagues are amazed that, at of cellular and molecular physiology. still like to do my own experiments. I three-dimensional sheets and helices 54, Horwich still enjoys the rigors of The Bohmfalk Prize for teaching like to be able to live with and suffer of a functioning protein. running experiments. “He seems to clinical science went to Michael K. through the problems of understand- But in 1987, Horwich and col- have retained the enthusiasm for O’Brien, .., .., assistant clini- ing how things work side by side with leagues discovered that sometimes science that people who are more my own people, and I always have one proteins need help from other special- senior seem to lose—the day-to-day cal professor of surgery. or two things for myself that I consider ized proteins, aptly known as “chaper- excitement,” says Tony Hunter, ph.d., a Sharon K. Inouye, .., ..., my own laboratory struggle.” onins,” which serve as intracellular cell biologist at the Salk Institute and a professor of medicine, received the In his first-floor lab at the Boyer protein-folding machines. Horwich fellow Gairdner winner who was one Leonard Tow Humanism in Medicine Center for Molecular Medicine, was impressed to discover that these of Horwich’s early mentors. Award, while Catherine Chiles, .., Horwich has helped to solve, bit by bit, molecular chaperones will try up to 20 In his spare time, Horwich enjoys associate clinical professor of psychia- one aspect of what has long been times to properly fold an intractable fly-fishing, tennis and backpacking. try, won the Leah M. Lowenstein known as “the protein-folding protein. In terms of the energy the cell But after a few days on the river or in Prize, for excellence in the promotion problem,” the question of how newly must expend, Horwich notes,“it’s a the mountains, he’s eager to get back of egalitarian medical education. The made proteins transform from long very expensive process,” but misfold- to the Boyer Center. Each day in the first annual Alvin R. Feinstein Award chains of amino acids into three- ing is costly, too: misfolded proteins lab holds out the chance, however for outstanding clinical skills was dimensional structures. This folding are linked to hundreds of devastating small, he says,“to see something that’s . step is essential, because the shapes of disorders, including Alzheimer’s, not been seen before. There’s no sub- awarded to Ronald R. Salem, ., folded proteins determine their func- Parkinson’s and mad cow disease. stitute for it.” associate professor of surgery. tions; for proteins, loosely speaking, “This work is as basic to biology as Robert D. Auerbach, .., lec- anatomy is destiny. understanding the nature of genes turer in obstetrics, gynecology and Lifelines profiles the people who carry out the sci- Horwich’s work has built upon and how genes are expressed and entific, educational and clinical missions of the Yale reproductive sciences, was awarded that of Nobel laureate and biochemist translated into proteins,” says Richard School of Medicine.
Recommended publications
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Chadi Abdallah, M.D. Associate Member Yale University Ted Abel
    Chadi Abdallah, M.D. Ted Abel, Ph.D. James Abelson, M.D., Ph.D Associate Member Fellow Member Emeritus Yale University University of Iowa University of Michigan Elizabeth Abercrombie, Ph.D. Anissa Abi-Dargham, M.D. Megumi Adachi, Ph.D. Fellow Fellow Associate Member Rutgers University Stony Brook University Astellas Research Institute R. Alison Adcock, M.D., Ph.D Nika Adham, B.Sc., M.Sc., Ph.D. Bryon Adinoff, M.D. Associate Member Member Fellow Emeritus Duke University Allergan, Inc. University of Colorado Caleb Adler, M.D. Martin Adler, Ph.D. George Aghajanian, M.D. Member Fellow Emeritus Fellow Emeritus University of Cincinnati Temple University Yale University Bernard Agranoff, B.S., M.D. Susanne Ahmari, M.D., Ph.D Katherine Aitchison, FRCPsy, Prof. Dr. Fellow Emeritus Member med University of Michigan University of Pittsburgh Member University of Alberta Howard Aizenstein, M.D., Ph.D Olusola Ajilore, M.D., Ph.D Schahram Akbarian, M.D., Ph.D Member Member Member University of Pittsburgh University of Illinois at Chicago Icahn School of Medicine At Mount Sinai Huda Akil, Ph.D. Martin Alda, FRCPC, M.D. Robert Alexander, M.D. Fellow Member Member University of Michigan Dalhousie University Takeda George Alexopoulos, M.D. Tanya Alim, M.D. Murray Alpert, Ph.D. Fellow Emeritus Member Fellow Emeritus Weill Cornell Medical College Howard University Larry Alphs, M.D., Ph.D C. Anthony Altar, Ph.D. Susan Amara, Ph.D. Member Member Emeritus Fellow Newron Pharmaceuticals Verge Genomics, Inc National Institute of Mental Health Stephanie Ameis, FRCP(C), M.D., M.Sc. Susan Andersen, Ph.D.
    [Show full text]
  • Serotonin Model of Schizophrenia: Emerging Role of Glutamate Mechanisms 1
    Brain Research Reviews 31Ž. 2000 302±312 www.elsevier.comrlocaterbres Interactive report Serotonin model of schizophrenia: emerging role of glutamate mechanisms 1 George K. Aghajanian ), Gerard J. Marek Departments of Psychiatry and Pharmacology, Yale UniÕersity School of Medicine and the Connecticut Mental Health Center, 34 Park St., New HaÕen, CT 06508, USA Accepted 30 June 1999 Abstract The serotoninŽ. 5-HT hypothesis of schizophrenia arose from early studies on interactions between the hallucinogenic drug LSD Ž.D-lysergic acid diethylamide and 5-HT in peripheral systems. More recent studies have shown that the two major classes of psychedelic hallucinogens, the indoleaminesŽ. e.g., LSD and phenethylamines Ž e.g., mescaline . , produce their central effects through a common action upon 5-HT2 receptors. This review focuses on two brain regions, the locus coeruleus and the cerebral cortex, where the actions of indoleamine and the phenethylamine hallucinogens have been shown to be mediated by 5-HT2A receptors; in each case, the hallucinogens Ž.via 5-HT2A receptors have been found to enhance glutamatergic transmission. In the prefrontal cortex, 5-HT2A -receptors stimulation increases the release of glutamate, as indicated by a marked increase in the frequency of excitatory postsynaptic potentialsrcurrents Ž.EPSPsrEPSCs in the apical dendritic region of layer V pyramidal cells; this effect is blocked by inhibitory group IIrIII metabotropic glutamate agonists acting presynaptically and by an AMPArkainate glutamate antagonist, acting postsynaptically at non-NMDA glutamate receptors. A major alternative drug model of schizophrenia, previously believed to be entirely distinct from that of the psychedelic hallucinogens, is based on the psychotomimetic properties of antagonists of the NMDA subtype of glutamate receptorŽ e.g., phencylidine and ketamine.
    [Show full text]
  • Ketamine Psychedelic Psychotherapy: Focus on Its Pharmacology, Phenomenology, and Clinical Applications Eli Kolp Private Practice
    International Journal of Transpersonal Studies Volume 33 | Issue 2 Article 8 7-1-2014 Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications Eli Kolp Private Practice Harris L. Friedman University of Florida Evgeny Krupitsky St. Petersburg State Pavlov Medical University Karl Jansen Auckland Hospital Mark Sylvester Private Practice See next page for additional authors Follow this and additional works at: https://digitalcommons.ciis.edu/ijts-transpersonalstudies Part of the Philosophy Commons, Psychiatry and Psychology Commons, and the Religion Commons Recommended Citation Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., & Kolp, A. (2014). Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., & Kolp, A. (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33(2), 84–140.. International Journal of Transpersonal Studies, 33 (2). http://dx.doi.org/10.24972/ijts.2014.33.2.84 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This Special Topic Article is brought to you for free and open access by the Journals and Newsletters at Digital Commons @ CIIS. It has been accepted for inclusion in International Journal of Transpersonal Studies by an authorized administrator of Digital Commons @ CIIS. For more information, please contact [email protected]. Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications Authors Eli Kolp, Harris L. Friedman, Evgeny Krupitsky, Karl Jansen, Mark Sylvester, M. Scott ounY g, and Anna Kolp This special topic article is available in International Journal of Transpersonal Studies: https://digitalcommons.ciis.edu/ijts- transpersonalstudies/vol33/iss2/8 Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications Eli Kolp Harris L.
    [Show full text]
  • Chadi Abdallah, M.D. Associate Member Baylor College of Medicine
    Chadi Abdallah, M.D. Ted Abel, Ph.D. James Abelson, M.D.,Ph.D. Associate Member Fellow Member Emeritus Baylor College of Medicine University of Iowa, Carver College of University of Michigan Health System Medicine Anissa Abi-Dargham, M.D. Megumi Adachi, Ph.D. R. Alison Adcock, M.D.,Ph.D. Fellow Associate Member Associate Member Stony Brook University Astellas Research Institute of America Duke University LLC Nii Addy, Ph.D. Nika Adham, B.Sc.,M.Sc.,Ph.D. Bryon Adinoff, M.D. Associate Member Member Fellow Emeritus Yale University School of Medicine Abbvie University of Colorado Medical School Caleb Adler, M.D. Martin Adler, Ph.D. George Aghajanian, M.D. Member Fellow Emeritus Fellow Emeritus University of Cincinnati College of Temple University School of Medicine Yale University School of Medicine Medicine Bernard Agranoff, B.S.,M.D. Susanne Ahmari, M.D.,Ph.D. Katherine Aitchison, Fellow Emeritus Member B.A.,FRCPsych,Ph.D. University of Michigan University of Pittsburgh Member University of Alberta Howard Aizenstein, M.D.,Ph.D. Olusola Ajilore, M.D.,Ph.D. Schahram Akbarian, M.D.,Ph.D. Member Member Member University of Pittsburgh University of Illinois at Chicago Icahn School of Medicine At Mount Sinai Huda Akil, Ph.D. Martin Alda, FRCPC,M.D. Robert Alexander, M.D. Fellow Member Member University of Michigan Dalhousie University Takeda George Alexopoulos, M.D. Tanya Alim, M.D. Murray Alpert, Ph.D. Fellow Emeritus Member Fellow Emeritus Weill Cornell Medical College Howard University Larry Alphs, M.D.,Ph.D. C. Anthony Altar, Ph.D. Susan Amara, Ph.D.
    [Show full text]
  • AN ORAL HISTORY of NEUROPSYCHOPHARMACOLOGY the FIRST FIFTY YEARS Peer Interviews
    AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY THE FIRST FIFTY YEARS Peer Interviews Volume Two: Neurophysiology Copyright © 2011 ACNP Thomas A. Ban (series editor) AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY Max Fink (volume editor) VOLUME 2: Neurophysiology All rights reserved. No part of this book may be used or reproduced in any manner without written permission from the American College of Neuropsychopharmacology (ACNP). Library of Congress Cataloging-in-Publication Data Thomas A. Ban, Max Fink (eds): An Oral History of Neuropsychopharmacology: The First Fifty Years, Peer Interviews Includes bibliographical references and index ISBN: 1461161452 ISBN-13: 9781461161455 1. Electroencephalography and neurophysiology 2. Pharmaco-EEG 3. Sleep EEG 4. Cerebral blood flow 5. Brain metabolism 6. Brain imaging Publisher: ACNP ACNP Executive Office 5034A Thoroughbred Lane Brentwood, Tennessee 37027 U.S.A. Email: [email protected] Website: www.acnp.org Cover design by Jessie Blackwell; JBlackwell Design www.jblackwelldesign.com AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY THE FIRST FIFTY YEARS Peer Interviews Edited by Thomas A. Ban Co-editors Volume 1: Starting Up - Edward Shorter Volume 2: Neurophysiology - Max Fink Volume 3: Neuropharmacology - Fridolin Sulser Volume 4: Psychopharmacology - Jerome Levine Volume 5: Neuropsychopharmacology - Samuel Gershon Volume 6: Addiction - Herbert D. Kleber Volume 7: Special Areas - Barry Blackwell Volume 8: Diverse Topics - Carl Salzman Volume 9: Update - Barry Blackwell Volume 10: History of the ACNP - Martin M. Katz VOLUME 2 NEUROPHYSIOLOGY ACNP 2011 VOLUME 2 Max Fink NEUROPHYSIOLOGY Preface Thomas A. Ban Dedicated to the Memory of Jonathan O. Cole, President ACNP, 1966 PREFACE Thomas A. Ban In Volume 1 of this series, 22 clinicians and basic scientists reflected on their contributions to the “starting up” of neuropsychopharmacology (NPP).
    [Show full text]
  • Tuesday, December 14 Poster Session II
    Neuropsychopharmacology (2004) 29, S127-S182 © 2004 Nature Publishing Group All rights reserved 0893-133X/04 www.neuropsychopharmacology.org S127 Tuesday, December 14 that does not activate ganglion or muscle-type nicotinic acetylcholine Poster Session II - Tuesday receptors. It is orally active, has shown long lasting cognitive effects in animal models and neuroprotective effects in vitro. Methods: Four early placebo-controlled studies in humans have been completed and 1. Effect of Memantine on Behavioral Outcomes in Moderate to partial data from a fifth are available (N=124). The completed stud- Severe Alzheimer’s Disease ies include SRD, MRD, food interaction and a PK in the elderly. Sin- Jeffrey L Cummings*,Eugene Schneider, Pierre N Tariot and gle doses up to 320mg and multiple doses for 10 days up to 200mg, Stephen M Graham have been explored. An ongoing study in elderly subjects with age as- Department of Neurology, University of California Los Angeles, Los sociated memory impairment (AAMI) involves three-week dosing up Angeles, CA, USA to 150mg. Safety/Tolerability: The drug was well tolerated overall. No changes of clinical significance were detected on biochemistry Memantine is a low-moderate affinity, uncompetitive N- testing, urine analysis, vital signs, ECG or 24-hour Holter monitor- methyl-D-aspartate (NMDA) receptor antagonist approved for the ing. Adverse events (AEs) were mild to moderate in intensity. Severe treatment of moderate to severe Alzheimer’s disease (AD). Excitotox- AEs were only seen at MTD - identifed in these studies as 320mg in icity mediated by NMDA receptors is thought to play a role in the the young and 150mg in the elderly.
    [Show full text]
  • Noradrenergic Regulation of Serotonergic Neurons in the Dorsal Raphe : Physiological, Pharmacological, and Anatomical Studies Jay Matthew Ab Raban Yale University
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1980 Noradrenergic regulation of serotonergic neurons in the dorsal raphe : physiological, pharmacological, and anatomical studies Jay Matthew aB raban Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Baraban, Jay Matthew, "Noradrenergic regulation of serotonergic neurons in the dorsal raphe : physiological, pharmacological, and anatomical studies" (1980). Yale Medicine Thesis Digital Library. 2374. http://elischolar.library.yale.edu/ymtdl/2374 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Digitized by the Internet Archive in 2017 with funding from The National Endowment for the Humanities and the Arcadia Fund https://archive.org/details/noradrenergicregOObara ABSTRACT NORADRENERGIC REGULATION OF SEROTONERGIC NEURONS IN THE DORSAL RAPHE: PHYSIOLOGICAL, PHARMACOLOGICAL AND ANATOMICAL STUDIES Jay Matthew Baraban Yale University 1980 Recent pharmacological studies suggest that a central nor¬ adrenergic (NE) system regulates the firing activity of the serotonin (5-HT)-containing neurons in the dorsal raphe nucleus. Reduction of noradrenergic tone by a variety of pharmacological interventions leads to a suppression of 5-HT cell firing (Svensson et al., 1975). It has been suggested that an alpha-adrenoceptor mediates NE's effects since systemic administration of an alpha-adrenoceptor antagonist, piperoxan, reduces 5-HT cell firing (Gallager and Aghajanian, 1976a).
    [Show full text]
  • Feeling Good Mental Health and Its Opposite
    Feeling good Mental health and its opposite Spring 2019 ALSO 4 New stem-cell extraction procedure / 7 The transformation of the Medical Library / 42 Long career of service Features 12/ Rethinking mental illness A look at the state of mental health and its inverse, mental illness, from Yale School of Medicine faculty and researchers from the departments of psychiatry and neuroscience. By Steve Hamm 18/ Breaking the cycle of traumatic memories Trials offering ketamine doses to patients suffering from post-traumatic stress disorder give some veterans hope that they can live a normal life. By Courtney McCarroll 22/ Taking psychiatric help to the street Emma Lo, MD, a fourth-year resident in Yale School of Medicine’s psychiatry program, spearheads a street psychiatry team many hope will help manage Connecticut’s part of the national substance use disorder epidemic. By Steve Hamm 24/ Brain bank aids theories on genetics and post-traumatic stress disorder Yale School of Medicine researchers use a massive brain-tissue repository, or “brain bank,” at the VA’s National Center for PTSD to postulate generalizations about the genetic origins of the condition and its physiological characteristics. By Jenny Blair, MD ’04 28/ Computational psychiatry: Modeling the brain’s neural circuitry Alan Anticevic, PhD, and John Murray, PhD, have combined efforts in order to under- stand the biology that underpins the brain’s neural system. By Katherine L. Kraines 30/ Why concussions hurt some people more than others Researchers are examining the relationship between concussions and depression in the hope of understanding why some people develop more extreme symptoms than others.
    [Show full text]
  • DOI-Induced Activation of the Cortex: Dependence on 5-HT2A Heteroceptors on Thalamocortical Glutamatergic Neurons
    The Journal of Neuroscience, December 1, 2000, 20(23):8846–8852 DOI-Induced Activation of the Cortex: Dependence on 5-HT2A Heteroceptors on Thalamocortical Glutamatergic Neurons Jennifer L. Scruggs,* Sachin Patel,* Michael Bubser, and Ariel Y. Deutch Departments of Psychiatry and Pharmacology and Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee 37212 Administration of the hallucinogenic 5-HT2A/2C agonist 1-[2,5- band of Fos immunoreactive neurons was in register with antero- dimethoxy-4-iodophenyl]-2-aminopropane (DOI) induces ex- gradely labeled axons from the ventrobasal thalamus, which pression of Fos protein in the cerebral cortex. To understand the have previously been shown to be glutamatergic and express the mechanisms subserving this action of DOI, we examined the 5-HT2A transcript. The effects of DOI were markedly reduced in consequences of pharmacological and surgical manipulations on animals pretreated with the AMPA/KA antagonist GYKI 52466, DOI-elicited Fos expression in the somatosensory cortex of the and lesions of the ventrobasal thalamus attenuated DOI-elicited rat. DOI dose-dependently increased cortical Fos expression. Fos expression in the cortex. These data suggest that DOI Pretreatment with the selective 5-HT2A antagonist MDL 100,907 activates 5-HT2A receptors on thalamocortical neurons and completely blocked DOI-elicited Fos expression, but pretreat- thereby increases glutamate release, which in turn drives Fos ment with the 5-HT2C antagonist SB 206,553 did not modify expression in cortical neurons through an AMPA receptor- DOI-elicited Fos expression. These data suggest that DOI acts dependent mechanism. These data cast new light on the mech- through 5-HT2A receptors to increase cortical Fos expression.
    [Show full text]
  • Serotonin, Via 5-HT Receptors, Increases Epscs in Layer V
    Brain Research 825Ž. 1999 161±171 Research report Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release George K. Aghajanian ), Gerard J. Marek Departments of Psychiatry and Pharmacology, Yale School of Medicine, Yale UniÕersity, New HaÕen, CT 06508, USA Connecticut Mental Health Center, 34 Park St., New HaÕen, CT 06508, USA Accepted 9 February 1999 Abstract Previously, serotoninŽ. 5-HT was found to induce a marked increase in glutamatergic spontaneous excitatory postsynaptic currents Ž.EPSCs in apical dendrites of layer V pyramidal cells of prefrontal cortex; this effect was mediated by 5-HT2A receptors, a proposed site of action of hallucinogenic and atypical antipsychotic drugs. Unexpectedly, although the effect of 5-HT was Ca2q-dependent and tetrodotoxin-sensitive, it did not appear to involve the activation of excitatory afferent impulse flow. This paradox prompted us to investigateŽ. in rat brain slices whether 5-HT was acting through an atypical mode of excitatory transmitter release. We found that the frequency of 5-HT-induced spontaneous EPSCs was fully supported by Sr 2q in the absence of added Ca2q, implicating the mechanism of asynchronous transmitter release which has been linked to the high-affinity Ca2q-sensor synaptotagmin III. Although the early, synchronous component of electrically eÕoked EPSCs was reduced while 5-HT was being applied, late, nonsynchronous components were enhanced during 5-HT washout and also by the 5-HT2 partial agonist 1-ŽŽ. 2,5-dimethoxy-4-iodophenyl-2-aminopropane DOI ; the effect of DOI was blocked by a selective 5-HT2A antagonistŽ.
    [Show full text]
  • Hallucinogens
    Pharmacology & Therapeutics 101 (2004) 131–181 www.elsevier.com/locate/pharmthera Associate editor: B.L. Roth Hallucinogens David E. Nichols* Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907-2091, USA Abstract Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes. They are considered physiologically safe and do not produce dependence or addiction. Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts. In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain. These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, especially those expressed on neocortical pyramidal cells. Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents. These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC). In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metabolism, and correlations have been developed between activity in specific brain areas and psychological elements of the ASC produced by hallucinogens.
    [Show full text]